Arbutus Biopharma (NASDAQ:ABUS – Get Free Report) posted its quarterly earnings data on Thursday. The biopharmaceutical company reported ($0.07) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.08) by $0.01, Zacks reports. The business had revenue of $1.57 million during the quarter, compared to analyst estimates of $2.20 million. Arbutus Biopharma had a negative return on equity of 68.18% and a negative net margin of 1,137.65%.
Arbutus Biopharma Stock Up 5.4 %
ABUS traded up $0.18 on Friday, reaching $3.45. 446,819 shares of the company traded hands, compared to its average volume of 1,032,072. The company has a market cap of $652.80 million, a P/E ratio of -8.03 and a beta of 1.93. The firm has a fifty day simple moving average of $3.33 and a two-hundred day simple moving average of $3.58. Arbutus Biopharma has a one year low of $2.30 and a one year high of $4.73.
Analyst Ratings Changes
Several research analysts have commented on ABUS shares. StockNews.com lowered shares of Arbutus Biopharma from a “hold” rating to a “sell” rating in a research note on Thursday, March 13th. Chardan Capital reiterated a “buy” rating and set a $5.00 price target on shares of Arbutus Biopharma in a report on Friday. Finally, HC Wainwright restated a “buy” rating and set a $5.00 target price on shares of Arbutus Biopharma in a research report on Tuesday, January 21st. One investment analyst has rated the stock with a sell rating and four have assigned a buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $5.50.
About Arbutus Biopharma
Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression.
Read More
- Five stocks we like better than Arbutus Biopharma
- What is a Stock Market Index and How Do You Use Them?
- Why Dollar Tree’s Family Dollar Sale Could Spark a Comeback
- What is a support level?
- JPMorgan: The ‘NVIDIA of Banking’ Poised for More Gains?
- When to Sell a Stock for Profit or Loss
- Buy the Chewy Stock Reversal? Here’s Why Now Is the Time
Receive News & Ratings for Arbutus Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arbutus Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
